• Skip to primary navigation
  • Skip to main content
  • Skip to footer
AKRN

AKRN

Scientific Consulting

  • Contact
  • LinkedIn

Performance Studies for SARS-CoV-2 IVD tests

March 1, 2022 by AKRN

Performance studies for SARS-CoV-2 IVD tests have become a hot topic since the publication of the MDCG 2021-21 and the common list of COVID-19 IVD tests. These two documents have strengthened the requirements to place SARS-CoV-2 IVD tests in the EU Market. Consequently, manufacturers are forced, in some cases, to demonstrate the analytical and clinical performance of their IVDs adequately. Hence, we have prepared a practical article to support manufacturers and pave their way to understanding SARS-CoV-2 IVD performance studies.

SARS-CoV-2 IVD tests

There are different types of SARS-CoV-2 diagnostic tests available in the market according to the analyte measured. The list of available tests is simplified to (1) detecting or quantifying SARS-CoV-2 nucleic acids, (2) antigens (specific proteins or whole virus) and (3) antibodies against the virus. Regardless of the analyte they measure, these tests are all classified as IVDs in the context of conformity assessment under either Directive 98/79/EC (IVDD) or Regulation (EU) 2017/746 (IVDR).

Scheme of the three types of SARS-CoV-2 diagnostic strategies:
1. Type 1 Molecular: Nucleic acid amplification tests
2. Type 2 Antigens: Structural SARS-CoV-2 proteins or whole virus
3. Type 3 Serological: Antibodies against SARS-CoV-2

Due to higher accuracy and reliability, nucleic acid amplification tests (NAAT, type 1) remain the “gold standard” for COVID-19 diagnosis. On the other hand, rapid antigen tests (RATs, type 2), though being generally less accurate than NAATs, are increasingly being used to maximize testing capacities while shortening turnaround times and reducing costs.

Overall, the unprecedented demand for SARS-CoV-2 tests due to the COVID-19 pandemic has filled the market with many IVD testing options. Most of them have not undergone conformity assessment through notified bodies and have used self-certification strategies under the IVDD (EU). Consequently, this situation has derived in significant numbers of substandard tests being made available on the market.

To overcome the lack of reliability for certain IVD tests, the EU has strengthened the requirements to place SARS-CoV-2 IVD tests on the market. Therefore, a significant number of manufacturers are now asked to perform new performance studies to comply with EU guidance. Additionally, the European Commission has created a database for all CE-marked COVID-19 IVDs where available information on COVID-19 tests performance is collected. This database is manually curated and periodically updated.

First things first: Analytical and Clinical Performance Studies

Performance studies shall focus on obtaining both analytical and clinical performance data. According to the in vitro diagnostics medical device regulation (IVDR) and the guidance document for Clinical Evidence for IVD medical devices GHTF/SG5/N6:2012, analytical and clinical performance are defined as follows:

  • Analytical performance means the ability of a device to correctly detect or measure a particular analyte.

Its demonstration is determined by analytical performance studies, which may include analytical sensitivity (e.g. limit of detection), analytical specificity (e.g. interference, cross-reactivity), accuracy (derived from trueness and precision) and linearity.

  • Clinical performance means the ability of a device to yield results that are correlated with a particular clinical condition or a physiological or pathological process or state in accordance with the target population and intended user.

Clinical performance data can be derived from multiple sources such as clinical performance studies, literature or experience gained by routine diagnostic testing. Commonly, such data include diagnostic sensitivity, diagnostic specificity, negative and positive predictive values.

Consider visiting the following link to learn more about clinical performance studies under the IVDR 2017/746.

Image illustrating scientists working in a laboratory. The image contains two people, a woman and a man, with labcoats and working with lab material.

Performance Studies for SARS-CoV-2 IVD tests

Performance studies of SARS-CoV-2 IVDs are mainly designed to establish two parameters: sensitivity and specificity (both analytical and diagnostic), although this may vary depending on the type of test evaluated. Supporting guidance on how to evaluate these parameters is provided by the Medical Device Coordinating Group (MDCG), which released a guidance document for the performance evaluation of SARS-CoV-2 IVDs (MDCG 2021-21).

MDCG 2021-21 forms the basis for the SARS-CoV-2 IVDs common specifications that will need to be followed by IVD manufacturers. In addition, MDCG 2021-21 complements the IVDR by clarifying how to measure the analytical and clinical performance, including new terms such as robustness or system-wide failure.

Last but not least, the guidance specifies the need to carry out the SARS-CoV-2 IVDs Performance Evaluation on a population equivalent to the European population. This is particularly important to third country manufacturers of SARS-CoV-2 in vitro diagnostic medical devices.

Please visit the following link to get more information about MDCG 2021-21.

EU Common list for Rapid Antigen Tests

Among the different SARS-CoV-2 IVDs referenced in the above mention guidelines, RATs have been pointed out as complementary screening tools to PCRs (which belong to the type 2, NAAT category) to keep the spread of the virus globally under control. Some RATs, however, were placed on the market with underperforming results regarding specificity and sensitivity. Thus, in conjunction with the Member States, the Health Security Committee (HSC) set a common list of appropriate RATs to allow the mutual recognition of COVID-19 test results across the EU.

The EU COVID-19 common list includes RATs from nasopharyngeal specimens that fulfill the following conditions:

  1. CE-marked;
  2. ≥90% sensitivity and ≥97% specificity;
  3. Validated at least by one EU Member State.

Note that rapid antigen self-tests are not included in this list.

An important consideration is that it is possible for manufacturers to submit data and information concerning rapid antigen tests that they believe should be considered for inclusion in the HSC agreed common list. This information will then be reviewed and considered alongside the proposals put forward by the EU Member States.

How can AKRN help?

Businessman and woman shake hands as hello in office closeup. Friend welcome, introduction, greet or thanks gesture, product advertisement, partnership approval, arm, strike a bargain on deal concept

Manufacturers/sponsors may choose to appoint a medical device Clinical Research Organization (CRO) to seek regulatory approvals and set up and manage the clinical performance study.

AKRN has the clinical experience, the regulatory knowledge and the staff qualifications to conduct clinical performance studies and elaborate the performance study reports. Additionally, we are experts in preparing performance evaluation plans, reports, and all the necessary technical documentation for Notified Body conformity assessments.

Subject Matter Experts

Ruben Ruiz, M.Sc.
Clinical Affairs Manager
LinkedIn

Lucía García, M.Sc. Clinical Research Scientist
LinkedIn

Share this article

Category iconCE Mark,  Clinical Evaluation Report,  Clinical Investigation,  Clinical Trial,  In vitro diagnostic devices,  IVDD,  IVDR,  MedTech,  Notified Body,  rapid test,  Regulatory Affairs Tag iconanalytical performance,  analytical performance studies,  clinical performance,  clinical performance studies,  COVID-19,  COVID-19 tests,  IVD Directive (IVDD),  IVD medical devices,  IVDR,  IVDR; In-Vitro Medical Devices,  IVDs,  Performance studies,  Rapid antigen tests,  Rapid tests,  SARS-CoV-2,  SARS-CoV-2 tests

Request a free consultation

Our team will help you to find the best solution for your needs. Our medical device experience and clinical knowledge can help you plan, set up, and execute a clinical trial, or performance study, in an optimal way.

Footer

AKRN Spain

AKRN Scientific Consulting S.L.
Address: Calle de Fuerteventura 4 (office 1.8)
Office Park La Marina
Postal Code: ES-28703 Madrid
Phone: +34 910 25 81 40
VAT ID: ES-B87990925

Contact details

Office phone: +34 910 258 140
Office phone: +34 919 333 814
Go to contact

Content

  • Contact

Resources

  • Articles
  • Resources

Latest articles

  • NAMSA AND ÅKRN: PROVIDING FULL CONTINUUM MEDTECH DEVELOPMENT SOLUTIONS
  • Artificial Intelligence challenges in Medical Devices
  • What is good clinical practice (GCP)?
  • Drug or Device? Summary and analysis of MDCG 2022-05 on borderline products
  • TRANSITIONAL PROVISIONS according to (EU) 2017/746 ARTICLE 110 IVDR, AN UPDATE WITH MDCGs published in 2022.
  • FELLOW PROGRAM – THE TALENT INCUBATOR OF A CRO

AKRN, Now part of NAMSA, is now ISO 9001:2015 quality certified by EQA, a recognized Spanish accredited certification body. The ISO 9001 standard, established by the International Organization for Standardization (ISO), is the quality standard par excellence, and its structure forms the basis for other quality standards such as the medical device quality standard ISO 13485. Implementing ISO 9001:2015 aims to support organizations in enhancing their overall performance and client satisfaction.

AKRN Scientific Consulting S.L ha sido beneficiaria del Fondo Europeo de Desarrollo Regional cuyo objetivo es mejorar la competitividad de las Pymes y gracias al cual ha puesto en marcha un Plan de Marketing Digital Internacional con el objetivo de mejorar su posicionamiento online en mercados exteriores durante el año 2020. Para ello ha contado con el apoyo del Programa XPANDE DIGITAL de la Cámara de Comercio de Burgos.
“Una manera de hacer Europa”

AKRN Scientific Consulting S.L ha sido beneficiaria de la subvención de contratos de trabajo de la Comunidad de Madrid, cofinanciado por el Fondo Social Europeo y la Iniciativa de Empleo Juvenil, en el marco del Programa Operativo de Empleo Juvenil 2014-2020, gestionado por la Consejería de Economía, Empleo y Hacienda.

La empresa (AKRN Scientific Consulting S.L.) es beneficiaria del Programa “la Caixa” Empleo Joven de ayudas para el fomento de la contratación de personas jóvenes. Estas ayudas están cofinanciadas por el Programa Operativo de Empleo Juvenil / Iniciativa de Empleo Juvenil – Fondo Social Europeo y por la Fundación Bancaria “la Caixa”.

 

 

  • LinkedIn

Privacy policy – Cookie Policy – Legal Notice –  Copyright © 2023. All rights reserved. Return to top

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
AKRN

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

More information about our Cookie Policy